<SEC-DOCUMENT>0001140361-24-050007.txt : 20241220
<SEC-HEADER>0001140361-24-050007.hdr.sgml : 20241220
<ACCEPTANCE-DATETIME>20241220080101
ACCESSION NUMBER:		0001140361-24-050007
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20241220
FILED AS OF DATE:		20241220
DATE AS OF CHANGE:		20241220

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			InflaRx N.V.
		CENTRAL INDEX KEY:			0001708688
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			P7
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-38283
		FILM NUMBER:		241565162

	BUSINESS ADDRESS:	
		STREET 1:		WINZERLAER STR. 2
		CITY:			JENA
		STATE:			2M
		ZIP:			07745
		BUSINESS PHONE:		49 3641 508180

	MAIL ADDRESS:	
		STREET 1:		WINZERLAER STR. 2
		CITY:			JENA
		STATE:			2M
		ZIP:			07745

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Fireman B.V.
		DATE OF NAME CHANGE:	20170606
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>ef20040227_6k.htm
<DESCRIPTION>6-K
<TEXT>
<html>
  <head>
    <title></title>
    <!-- Licensed to: Broadridge
         Document created using Broadridge PROfile 24.12.1.5274
         Copyright 1995 - 2024 Broadridge -->
  </head>
<body bgcolor="#ffffff" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000;">
  <hr align="center" style="border: none; border-bottom: 1px solid black; border-top: 4px solid black; height: 10px; color: #ffffff; background-color: #ffffff; text-align: center; margin-left: auto; margin-right: auto;">
  <div>
    <div style="text-align: center; color: rgb(0, 0, 0); font-size: 14pt; font-weight: bold;">UNITED STATES</div>
    <div style="text-align: center; color: rgb(0, 0, 0); font-size: 14pt; font-weight: bold;">SECURITIES AND EXCHANGE COMMISSION</div>
    <div style="text-align: center; color: rgb(0, 0, 0); font-size: 12pt;">Washington, D.C. 20549</div>
    <div><br>
    </div>
    <div style="text-align: center; color: rgb(0, 0, 0); font-size: 18pt; font-weight: bold;">FORM 6-K</div>
    <div><br>
    </div>
    <div style="text-align: center; color: #000000; font-weight: bold;">Report of Foreign Private</div>
    <div style="text-align: center; color: #000000; font-weight: bold;">Issuer Pursuant to Rule</div>
    <div style="text-align: center; color: #000000; font-weight: bold;">13a-16 or 15d-16 of the</div>
    <div style="text-align: center; color: #000000; font-weight: bold;">Securities Exchange Act</div>
    <div style="text-align: center; color: #000000; font-weight: bold;">of 1934</div>
    <div style="text-align: center; color: #000000; font-weight: bold;">For the month of December 2024</div>
    <div style="text-align: center; color: #000000;">Commission File</div>
    <div style="text-align: center; color: #000000;">Number: 001-38283</div>
    <div><br>
    </div>
    <div style="text-align: center; color: rgb(0, 0, 0); font-size: 24pt; font-weight: bold;">InflaRx N.V.</div>
    <div><br>
    </div>
    <div style="text-align: center; color: #000000; font-weight: bold;">Winzerlaer Str. 2</div>
    <div style="text-align: center; color: #000000; font-weight: bold;">07745 Jena,</div>
    <div style="text-align: center; color: #000000; font-weight: bold;">Germany</div>
    <div style="text-align: center; color: #000000; font-weight: bold;">(+49) 3641508180</div>
    <div><br>
    </div>
    <div style="text-align: center; color: #000000;">(Address of principal executive offices)</div>
    <div><br>
    </div>
    <div style="color: #000000;">Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.</div>
    <div><br>
    </div>
    <div style="text-align: center; color: #000000;">Form 20-F &#9746; Form 40-F &#8201;&#9744;</div>
    <div style="text-align: center; color: #000000;"> <br>
    </div>
    <div>
      <hr align="center" style="border: none; border-bottom: 4px solid black; border-top: 1px solid black; height: 10px; color: #ffffff; background-color: #ffffff; text-align: center; margin-left: auto; margin-right: auto;"></div>
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
    </div>
    <div style="text-align: center; color: #000000; font-weight: bold;">INCORPORATION BY REFERENCE</div>
    <div><br>
    </div>
    <div style="text-align: justify; color: #000000;">On December 20, 2024, InflaRx N.V. (the &#8220;Company&#8221;) issued a press release titled &#8220;InflaRx Announces First Patient Dosed in Phase 2a Study for Oral C5aR Inhibitor INF904&#8221;.</div>
    <div><br>
    </div>
    <div style="text-align: justify; color: #000000;">The Company announced that the first patient has been dosed in its Phase 2a basket study in chronic spontaneous urticaria (&#8220;CSU&#8221;) and hidradenitis suppurativa (&#8220;HS&#8221;), investigating the Company&#8217;s oral
      C5aR inhibitor, INF904. The Phase 2a trial is a multi-center, open-label study expected to include a total of 75 patients with moderate-to-severe CSU and moderate-to-severe HS. The trial will evaluate multiple INF904 dosing regimens over four weeks
      of treatment to generate additional safety and pharmacokinetic data and to provide signs of clinical benefit. As previously disclosed, this basket study is utilizing a commercially viable formulation of INF904, providing a range of drug exposures
      comparable to the reported levels in the Phase 1 study. After the four-week treatment period, patients will be followed for an additional four weeks. Data from this study are expected in the summer of 2025, with a goal of informing the design of a
      larger, longer-term Phase 2b study by year-end 2025.</div>
    <div><br>
    </div>
    <div style="text-align: justify; color: #000000;">This report on Form 6-K (the &#8220;Report&#8221;) shall be deemed to be incorporated by reference into (i) the registration statements on Form S-8 (File No. 333-221656 and 333-240185) and (ii) the registration
      statement on Form F-3 (File No. 333-273058) of the Company and to be a part thereof from the date on which this Report is submitted, to the extent not superseded by documents or reports subsequently filed or furnished.</div>
    <div><br>
    </div>
    <div style="text-align: justify; color: #000000;">A copy of the press release is attached as Exhibit 99.1 to this Report. Exhibit 99.1 shall not be deemed &#8220;filed&#8221; for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the
      &#8220;Exchange Act&#8221;), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act.</div>
    <div><br>
    </div>
    <div style="text-align: justify; color: #000000; font-weight: bold;"><u>FORWARD-LOOKING STATEMENTS</u></div>
    <div><br>
    </div>
    <div style="text-align: justify; color: #000000;">This Report contains forward-looking statements. All statements other than statements of historical fact are forward-looking statements, which are often indicated by terms such as &#8220;may,&#8221; &#8220;will,&#8221;
      &#8220;should,&#8221; &#8220;expect,&#8221; &#8220;plan,&#8221; &#8220;anticipate,&#8221; &#8220;could,&#8221; &#8220;intend,&#8221; &#8220;target,&#8221; &#8220;project,&#8221; &#8220;estimate,&#8221; &#8220;believe,&#8221; &#8220;predict,&#8221; &#8220;potential&#8221; or &#8220;continue,&#8221; among others. Forward-looking statements appear in a number of places throughout this Report and may
      include statements regarding our intentions, beliefs, projections, outlook, analyses, current expectations and the risks, uncertainties and other factors described under the heading &#8220;Risk Factors&#8221; and &#8220;Cautionary statement regarding forward looking
      statements&#8221; in our periodic filings with the U.S. Securities and Exchange Commission. These statements speak only as of the date of this Report and involve known and unknown risks, uncertainties and other important factors that may cause our actual
      results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Given these risks, uncertainties and other factors, you should not place
      undue reliance on these forward-looking statements, and we assume no obligation to update these forward-looking statements, even if new information becomes available in the future, except as required by law.</div>
    <div><br>
    </div>
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
    </div>
    <div style="text-align: center; color: #000000; font-weight: bold;">EXHIBIT INDEX</div>
    <div><br>
    </div>
    <table cellspacing="0" cellpadding="0" border="0" id="z52b0e7df54e349bc8bcc4a317619d564" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;">

        <tr>
          <td style="width: 20%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);">
            <div style="color: rgb(0, 0, 0); font-weight: bold;">Exhibit No.</div>
          </td>
          <td style="width: 80%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);">
            <div style="color: rgb(0, 0, 0); font-weight: bold;">Description</div>
          </td>
        </tr>
        <tr>
          <td style="width: 20%; vertical-align: top;">
            <div style="color: rgb(0, 0, 0);"><a href="ef20040227_ex99-1.htm">99.1</a></div>
          </td>
          <td style="width: 80%; vertical-align: top;">
            <div style="color: rgb(0, 0, 0);">Press Release, dated December 20, 2024</div>
          </td>
        </tr>

    </table>
    <div><br>
    </div>
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
    </div>
    <div style="text-align: center; color: #000000; font-weight: bold;">SIGNATURES</div>
    <div><br>
    </div>
    <div style="text-align: justify; color: #000000;">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.</div>
    <div><br>
    </div>
    <table cellspacing="0" cellpadding="0" border="0" id="z6606b94305f14d9b854ed8032cba2a13" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;">

        <tr>
          <td style="width: 45%; vertical-align: top;"><br>
          </td>
          <td style="vertical-align: top;" colspan="2">
            <div style="text-align: justify; color: rgb(0, 0, 0); font-weight: bold;">INFLARX N.V.</div>
          </td>
        </tr>
        <tr>
          <td style="width: 45%; vertical-align: top;">
            <div style="text-align: justify; color: rgb(0, 0, 0);">Date: December 20, 2024</div>
          </td>
          <td style="width: 3%; vertical-align: top;">&#160;</td>
          <td style="width: 52%; vertical-align: top;">&#160;</td>
        </tr>
        <tr>
          <td style="width: 45%; vertical-align: top; padding-bottom: 2px;"><br>
          </td>
          <td style="width: 3%; vertical-align: top; padding-bottom: 2px;">
            <div style="text-align: justify; color: rgb(0, 0, 0);">By:</div>
          </td>
          <td style="width: 52%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);">
            <div style="text-align: justify; color: rgb(0, 0, 0);">/s/ Niels Riedemann</div>
          </td>
        </tr>
        <tr>
          <td style="width: 45%; vertical-align: top;"><br>
          </td>
          <td style="width: 3%; vertical-align: top;">&#160;</td>
          <td style="width: 52%; vertical-align: top;">
            <div style="text-align: justify; color: rgb(0, 0, 0);">Name: Niels Riedemann</div>
          </td>
        </tr>
        <tr>
          <td style="width: 45%; vertical-align: top;"><br>
          </td>
          <td style="width: 3%; vertical-align: top;">&#160;</td>
          <td style="width: 52%; vertical-align: top;">
            <div style="text-align: justify; color: rgb(0, 0, 0);">Title: Chief Executive Officer</div>
          </td>
        </tr>

    </table>
    <div><br>
    </div>
    <div><br>
    </div>
    <div>
      <hr noshade="noshade" align="center" style="height: 2px; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;"></div>
  </div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>ef20040227_ex99-1.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<html>
  <head>
    <title></title>
    <!-- Licensed to: Broadridge
         Document created using Broadridge PROfile 24.12.1.5274
         Copyright 1995 - 2024 Broadridge -->
  </head>
<body bgcolor="#ffffff" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000;">


  <div>
    <hr noshade="noshade" align="center" style="height: 4px; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;">
    <div style="text-align: right;"><font style="font-weight: bold;">Exhibit 99.1</font><br>
    </div>
    <div><br>
    </div>
    <div><img src="image00003.jpg"></div>
    <div><br>
    </div>
    <div>
      <div style="text-align: center;">InflaRx Announces First Patient Dosed in Phase 2a Study for Oral C5aR Inhibitor INF904</div>
      <div><br>
      </div>
      <div style="text-align: justify;"><font style="font-weight: bold;">Jena, Germany, December 20, 2024 </font>&#8211; InflaRx
          N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics targeting the complement system, today announced that the first patient has been dosed in its Phase 2a basket study in chronic spontaneous urticaria (CSU)
          and hidradenitis suppurativa (HS), investigating the Company&#8217;s oral C5aR inhibitor, INF904.</div>
      <div><br>
      </div>
      <div style="text-align: justify;"><font style="font-weight: bold;">Camilla Chong, MD, Chief Medical Officer of InflaRx, commented:</font> &#8220;We are pleased to have started our Phase 2a trial for INF904 with the first patient dosed at one of our U.S. sites, and I am very proud of our team who implemented this important study so rapidly. We believe there is
          strong evidence of INF904&#8217;s anti-inflammatory properties and that its best-in-class potential will go a long way to serve unmet medical needs in both chronic spontaneous urticaria and hidradenitis suppurativa, and in other immuno-inflammatory
          conditions as well.&#8221;</div>
      <div><br>
      </div>
      <div style="text-align: justify; font-weight: bold;">INF904 Phase 2a Study</div>
      <div style="text-align: justify;">The Phase 2a trial is a multi-center, open-label study expected to include a total of 75 patients with moderate-to-severe CSU and moderate-to-severe HS. The trial will
        evaluate multiple INF904 dosing regimens over 4 weeks of treatment to generate additional safety and pharmacokinetic (PK) data and to provide signs of clinical benefit. As previously disclosed, this basket study is utilizing a commercially viable
        formulation of INF904, providing a range of drug exposures comparable to the reported levels in the <u>Phase 1 study</u>. After the 4-week treatment period, patients will be followed for an additional 4 weeks. Data from this study are
        expected in the summer of 2025, with a goal of informing the design of a larger, longer-term Phase 2b study by year-end 2025.</div>
      <div><br>
      </div>
      <div style="text-align: justify;">In the CSU group, a total of 45 patients will be dosed in three study arms. Patients in Study Arms 1 and 2 will be randomized at a 1:1 ratio to 2 doses of INF904 at 60
        mg or 120 mg BID (twice daily), a range of drug exposures comparable to the Phase 1 trial. Patients in Study Arm 3 will be comprised of anti-<a name="z_Int_TqKcSnDx"></a>IgE treatment non-responders and dosed at 120 mg BID. In addition to safety
        and PK parameters, assessed CSU efficacy measures will include change in the Urticaria Activity Score 7 (UAS7), Hives Severity Score (HSS7) and Itch Severity Score (ISS7) from baseline to the end of week 4. Responder analyses, biomarkers and
        Patient-Reported Outcome (PRO) endpoints related to urticaria control and quality of life will also be assessed.</div>
      <div><br>
      </div>
      <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
        <div style="width: 100%;" class="BRPFPageHeader">
          <div>
            <div><img src="image00003.jpg"></div>
          </div>
        </div>
      </div>
      <div style="text-align: justify;">In the HS group, 30 patients will be randomized at a 1:1:1 ratio to 3 doses of INF904 at 60 mg, 90 mg or 120 mg BID, a range of drug exposures comparable to the Phase
        1 trial. In addition to safety and PK parameters, assessed HS efficacy measures will include change in total abscess, inflammatory nodule and draining tunnel (dT) count, HS lesions-related scores and Clinician&#8217;s Global Impression of Change (CGI-C)
        at 4 weeks. PRO endpoints related to HS disease control, pain and quality of life will also be assessed.</div>
      <div><br>
      </div>
      <div style="text-align: justify;">InflaRx believes CSU and HS each has potential addressable markets of $1 billion or more for INF904. The Company also believes INF904 could address meaningful
        opportunities in additional immuno-dermatology and immuno-inflammatory indications, including in nephrology, neurology and hematology. While InflaRx intends to focus its resources on its immediate goals addressing CSU and HS, the Company continues
        to assess and monitor the value of pursuing additional areas and applications via potential future collaborations with partners.</div>
      <div><br>
      </div>
      <div style="text-align: justify; margin-right: 3.7pt; font-style: italic; font-weight: bold;">About INF904</div>
      <div style="text-align: justify; margin-right: 3.7pt;">INF904 is an orally administered, small molecule inhibitor of the C5a receptor that has shown anti-inflammatory therapeutic effects in several
        pre-clinical disease models. Further, in contrast to the marketed C5aR inhibitor, in vitro experiments demonstrated that INF904 has minimal inhibition of the cytochrome P450 3A4/5 (CYP3A4/5) enzymes, which play an important role in the metabolism
        of a variety of metabolites and drugs, including glucocorticoids. Reported results from a first-in-human study demonstrated that INF904 is well tolerated in treated subjects and exhibits no safety signals of concern in single doses ranging from 3
        mg to 240 mg or multiple doses ranging from 30 mg once per day (QD) to 90 mg twice per day (BID) for 14 days. PK / pharmacodynamic data support the best-in-class potential of INF904 with a &#8805;90% blockade of C5a-induced neutrophil activation achieved
        over the 14-day dosing period.</div>
      <div><br>
      </div>
      <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
        <div style="width: 100%;" class="BRPFPageHeader">
          <div>
            <div><img src="image00003.jpg"></div>
          </div>
        </div>
      </div>
      <div style="text-align: justify; font-style: italic; font-weight: bold;">About InflaRx</div>
      <div style="text-align: justify;"><font style="color: #000000;">InflaRx (Nasdaq: IFRX) is a biopharmaceutical company pioneering anti-inflammatory
          therapeutics by applying its proprietary anti-C5a and anti-C5aR technologies to discover, develop and commercialize highly potent and specific inhibitors of the complement activation factor C5a and its receptor C5aR. C5a is a powerful
          inflammatory mediator involved in the progression of a wide variety of inflammatory diseases. InflaRx&#8217;s lead product candidate, vilobelimab, is a novel, intravenously delivered, first-in-class, anti-C5a monoclonal antibody that selectively binds
          to free C5a and has demonstrated disease-modifying clinical activity and tolerability in multiple clinical studies in different indications. InflaRx is also developing INF904, an orally administered small molecule inhibitor of the C5a receptor.
          InflaRx was founded in 2007, and the group has offices and subsidiaries in Jena and Munich, Germany, as well as Ann Arbor, MI, USA. For further information, please visit </font><u>www.inflarx.com</u><font style="color: rgb(0, 0, 0);">.</font></div>
      <div>&#160;</div>
      <div style="text-align: justify; color: #000000;">InflaRx GmbH (Germany) and InflaRx Pharmaceuticals Inc. (USA) are wholly owned subsidiaries of InflaRx N.V. (together, InflaRx).</div>
      <br>
      <table cellspacing="0" cellpadding="0" id="zebec16fbadcd41ad99ebd66750d04621" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;">

          <tr>
            <td style="width: 49.59%; vertical-align: top;">
              <div style="font-style: italic; font-weight: bold;">Contacts:</div>
            </td>
            <td style="width: 50.41%; vertical-align: top;"><br>
            </td>
          </tr>
          <tr>
            <td style="width: 49.59%; vertical-align: top;">
              <div style="margin-right: 3.7pt; font-weight: bold;">InflaRx N.V.</div>
            </td>
            <td style="width: 50.41%; vertical-align: top;">
              <div style="margin-right: 3.7pt; font-weight: bold;">MC Services AG</div>
            </td>
          </tr>
          <tr>
            <td style="width: 49.59%; vertical-align: top;">
              <div style="text-align: justify; margin-right: 3.7pt;">Jan Medina, CFA</div>
            </td>
            <td style="width: 50.41%; vertical-align: top;">
              <div style="text-align: justify; margin-right: 3.7pt;">Katja Arnold, Laurie Doyle, Dr. Regina Lutz</div>
            </td>
          </tr>
          <tr>
            <td style="width: 49.59%; vertical-align: top;">
              <div style="text-align: justify; margin-right: 3.7pt;">Vice President, Head of Investor Relations</div>
            </td>
            <td style="width: 50.41%; vertical-align: top;">
              <div style="text-align: justify; margin-right: 3.7pt;">Email: <u>inflarx@mc-services.eu</u></div>
            </td>
          </tr>
          <tr>
            <td style="width: 49.59%; vertical-align: top;">
              <div style="text-align: justify; margin-right: 3.7pt;">Email: <u>IR@inflarx.de</u></div>
            </td>
            <td style="width: 50.41%; vertical-align: top;">
              <div style="text-align: justify; margin-right: 3.7pt;">Europe: +49 89-210 2280</div>
            </td>
          </tr>
          <tr>
            <td style="width: 49.59%; vertical-align: top;"><br>
            </td>
            <td style="width: 50.41%; vertical-align: top;">
              <div style="text-align: justify; margin-right: 3.7pt;">U.S.: +1-339-832-0752</div>
            </td>
          </tr>

      </table>
      <div><br>
      </div>
      <div style="text-align: justify; margin-right: 3.95pt; font-weight: bold;">FORWARD-LOOKING STATEMENTS</div>
      <div style="text-align: justify; color: #000000;">This press release contains forward-looking statements. All statements other than statements of historical fact are forward-looking statements, which
        are often indicated by terms such as &#8220;may,&#8221; &#8220;will,&#8221; &#8220;should,&#8221; &#8220;expect,&#8221; &#8220;plan,&#8221; &#8220;anticipate,&#8221; &#8220;could,&#8221; &#8220;intend,&#8221; &#8220;target,&#8221; &#8220;project,&#8221; &#8220;estimate,&#8221; &#8220;believe,&#8221; &#8220;predict,&#8221; &#8220;potential&#8221; or &#8220;continue,&#8221; among others. Forward-looking statements appear in a
        number of places throughout this release and may include statements regarding our intentions, beliefs, projections, outlook, analyses, current expectations and the risks, uncertainties and other factors described under the heading &#8220;Risk Factors&#8221;
        and &#8220;Cautionary statement regarding forward looking statements&#8221; in our periodic filings with the U.S. Securities and Exchange Commission. These statements speak only as of the date of this press release and involve known and unknown risks,
        uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Given
        these risks, uncertainties and other factors, you should not place undue reliance on these forward-looking statements, and we assume no obligation to update these forward-looking statements, even if new information becomes available in the future,
        except as required by law.</div>
      <div><br>
      </div>
      <div><br>
      </div>
      <div>
        <hr noshade="noshade" align="center" style="height: 2px; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;"></div>
    </div>
  </div>


</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>image00003.jpg
<TEXT>
begin 644 image00003.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  8$!08%! 8&!08'!P8("A *"@D)
M"A0.#PP0%Q08&!<4%A8:'24?&ALC'!86("P@(R8G*2HI&1\M,"TH,"4H*2C_
MVP!# 0<'!PH("A,*"A,H&A8:*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H
M*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"C_P  1"  S )\# 2(  A$! Q$!_\0
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M'E1,X/N!Q3,C@O&OC^6QOI+#1PA>([9)F&?F[@#V]:Y:T\8^)6N(V%X[AF
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M(,,K$QF;_@(R/UQ7L7BRY^R>&M2E'40,H^IX_K63X3\%P>';^2ZCN7G=HS&
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;%*RQ7%K,LJ#HX"[AG\0#7VE110 4444 ?__9

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
